Nurix Therapeutics, Inc.
NRIX
$15.60
-$0.13-0.83%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.58M | 7.89M | 44.06M | 18.45M | 13.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.58M | 7.89M | 44.06M | 18.45M | 13.28M |
| Cost of Revenue | 83.02M | 86.12M | 78.10M | 69.66M | 67.22M |
| Gross Profit | -69.45M | -78.23M | -34.04M | -51.21M | -53.94M |
| SG&A Expenses | 13.65M | 13.16M | 14.28M | 11.65M | 10.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.67M | 99.28M | 92.38M | 81.32M | 77.94M |
| Operating Income | -83.10M | -91.39M | -48.32M | -62.86M | -64.66M |
| Income Before Tax | -78.22M | -86.42M | -42.70M | -56.35M | -58.54M |
| Income Tax Expenses | 0.00 | -- | 760.00K | -- | 8.00K |
| Earnings from Continuing Operations | -78.22M | -86.42M | -43.46M | -56.35M | -58.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.22M | -86.42M | -43.46M | -56.35M | -58.55M |
| EBIT | -83.10M | -91.39M | -48.32M | -62.86M | -64.66M |
| EBITDA | -81.58M | -89.36M | -46.08M | -60.51M | -63.41M |
| EPS Basic | -0.82 | -1.03 | -0.52 | -0.67 | -0.75 |
| Normalized Basic EPS | -0.51 | -0.64 | -0.32 | -0.42 | -0.47 |
| EPS Diluted | -0.82 | -1.03 | -0.52 | -0.67 | -0.75 |
| Normalized Diluted EPS | -0.51 | -0.64 | -0.32 | -0.42 | -0.47 |
| Average Basic Shares Outstanding | 95.09M | 84.16M | 83.88M | 83.56M | 78.41M |
| Average Diluted Shares Outstanding | 95.09M | 84.16M | 83.88M | 83.56M | 78.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |